Naratriptan dosage and administration: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Naratriptan}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NARATRIPTAN TABLET, COATED [SANDOZ INC] | url = http://dailym...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Dosage and Administration== | |||
In controlled clinical trials, single doses of 1 and 2.5 mg of naratriptan tablets, USP taken with fluid were effective for the acute treatment of migraines in adults. A greater proportion of patients had headache response following a 2.5 mg dose than following a 1 mg dose (see CLINICAL TRIALS). Individuals may vary in response to doses of naratriptan tablets, USP. The choice of dose should therefore be made on an individual basis, weighing the possible benefit of the 2.5 mg dose with the potential for a greater risk of adverse events. If the headache returns or if the patient has only partial response, the dose may be repeated once after 4 hours, for a maximum dose of 5 mg in a 24-hour period. There is evidence that doses of 5 mg do not provide a greater effect than 2.5 mg. | |||
The safety of treating, on average, more than 4 headaches in a 30-day period has not been established. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NARATRIPTAN TABLET, COATED [SANDOZ INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39c658d3-5bc8-4f81-9837-1c4edcf1b6c2 | publisher = | date = | accessdate = }}</ref> | ====Renal Impairment==== | ||
The use of naratriptan tablets, USP is contraindicated in patients with severe renal impairment (creatinine clearance, <15 mL/min) because of decreased clearance of the drug (see CONTRAINDICATIONS and CLINICAL PHARMACOLOGY). In patients with mild to moderate renal impairment, the maximum daily dose should not exceed 2.5 mg over a 24-hour period and a lower starting dose should be considered. | |||
====Hepatic Impairment==== | |||
The use of naratriptan tablets, USP is contraindicated in patients with severe hepatic impairment (Child-Pugh grade C) because of decreased clearance (see CONTRAINDICATIONS and CLINICAL PHARMACOLOGY). In patients with mild or moderate hepatic impairment, the maximum daily dose should not exceed 2.5 mg over a 24-hour period and a lower starting dose should be considered (seeCLINICAL PHARMACOLOGY).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NARATRIPTAN TABLET, COATED [SANDOZ INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39c658d3-5bc8-4f81-9837-1c4edcf1b6c2 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 20:02, 3 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Dosage and Administration
In controlled clinical trials, single doses of 1 and 2.5 mg of naratriptan tablets, USP taken with fluid were effective for the acute treatment of migraines in adults. A greater proportion of patients had headache response following a 2.5 mg dose than following a 1 mg dose (see CLINICAL TRIALS). Individuals may vary in response to doses of naratriptan tablets, USP. The choice of dose should therefore be made on an individual basis, weighing the possible benefit of the 2.5 mg dose with the potential for a greater risk of adverse events. If the headache returns or if the patient has only partial response, the dose may be repeated once after 4 hours, for a maximum dose of 5 mg in a 24-hour period. There is evidence that doses of 5 mg do not provide a greater effect than 2.5 mg.
The safety of treating, on average, more than 4 headaches in a 30-day period has not been established.
Renal Impairment
The use of naratriptan tablets, USP is contraindicated in patients with severe renal impairment (creatinine clearance, <15 mL/min) because of decreased clearance of the drug (see CONTRAINDICATIONS and CLINICAL PHARMACOLOGY). In patients with mild to moderate renal impairment, the maximum daily dose should not exceed 2.5 mg over a 24-hour period and a lower starting dose should be considered.
Hepatic Impairment
The use of naratriptan tablets, USP is contraindicated in patients with severe hepatic impairment (Child-Pugh grade C) because of decreased clearance (see CONTRAINDICATIONS and CLINICAL PHARMACOLOGY). In patients with mild or moderate hepatic impairment, the maximum daily dose should not exceed 2.5 mg over a 24-hour period and a lower starting dose should be considered (seeCLINICAL PHARMACOLOGY).[1]
References
Adapted from the FDA Package Insert.